3650 results for «403»
3650 results
Coronary interventions: first-in-man and novel devices
20 May 2026 – From EuroPCR 2026
Explore pioneering advancements in coronary interventions with first-in-man and novel devices. This session presents groundbreaking studies including cryotherapy for vulnerable plaques, a novel intravascular crossing system for coronary CTOs, sirolimus-coated retrievable scaffold therapy for in-stent restenosis, real-time intravascular photoacoustic imaging of lipid-rich plaques, and the inaugural...
Bifurcation PCI with complications - Part 2
20 May 2026 – From EuroPCR 2026
This session addresses the challenges and complications encountered during bifurcation PCI. Topics include managing the hairpin hazard, advanced techniques for coronary guidewire entrapment, dual device failure in complex interventions, strategies for trifurcation lesions, and the implications of tissue entrapment in malapposed stents within the left main...
When the anterior leaflet gets in the way: mitral leaflet modification before TMVR
19 May 2026 – From EuroPCR 2026
This session addresses the intricacies of mitral leaflet modification techniques prior to transcatheter mitral valve replacement (TMVR). It features innovative approaches such as LAMPOON-assisted valve-in-ring replacement, balloon-assisted leaflet translocation, and strategies to overcome the challenges posed by mitral annular calcification.
PCR's Got Talent Round 1 - Session 2
19 May 2026 – From EuroPCR 2026
PCR's Got Talent Round 1 - Session 2 offers a diverse collection of studies addressing coronary microvascular dysfunction, atrial fibrillation management, TAVI outcomes, AI applications in imaging, mitral and tricuspid valve interventions, and in-stent restenosis treatment. The session culminates with deliberations and results announcements, reflecting cutting-edge...
How to face resistent hypertension: when pharmacological treatment is not an option
19 May 2026 – From EuroPCR 2026
Focused on resistant hypertension, this session explores interventional options when pharmacological treatments fall short. It discusses urgent intervention indications, complex cases involving renal artery occlusion, and the role of fractional flow reserve (FFR) in managing pan-vascular disease associated with hypertension.
FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case
19 May 2026 – From EuroPCR 2026
A 71‑year‑old man with hypertension and dyslipidemia presented with CCS class II angina and three‑vessel coronary artery disease. Functional assessment included CT‑derived micro‑FFR, angiography‑based FFR, and stress myocardial scintigraphy. The only hemodynamically significant lesion was a long, calcified lesion of the LAD.
Lesion preparation was performed with...
TAVI procedural complications - Part 3: vascular complications, coronary issues and more
19 May 2026 – From EuroPCR 2026
This session addresses critical procedural complications during TAVI, emphasizing vascular issues, coronary complications, and complex bailout scenarios. Through challenging case examples, it offers insights into the management and anticipation of such complications to optimize patient outcomes.
Identifying problems and solving complex anatomies during TAVI
19 May 2026 – From EuroPCR 2026
A comprehensive session on managing complex anatomies during Transcatheter Aortic Valve Implantation (TAVI), emphasizing risk markers for peri-operative complications and strategies to address difficult anatomical challenges. Real-world cases illustrate practical approaches and key learnings for handling intricate TAVI scenarios.
FFR or 3d-quantitative coronary angiography-based vessel-FFR guided revascularisation – The FAST III trial
28 Mar 2026
Chiara De Biase provides her take on the FAST III Trial presented by Joost Daemen at ACC.26 in New Orleans. She reviews the comparison between vFFR and FFR, highlighting key findings and their impact on revascularisation strategies.
Author
Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease: the FLAVOUR II trial
29 Mar 2025
Ali Nazmi Calik provides his take on the FLAVOUR II trial presented by Jian-An Wang at ACC.25 in Chicago.
Author
